Impact of Elosulfase Alfa on Pain in Patients with Morquio A Syndrome over 52 Weeks: MOR-008: A Randomized, Double-Blind, Pilot Study
Treadwell, Marsha; Harmatz, Paul R.; Burton, Barbara K.; Mitchell, John J.; Muschol, Nicole; Jones, Simon A.; Pastores, Gregory M.; Lau, Heather A.; Sparkes, Rebecca; Sutton, V. Reid; Meesen, Bianca; Haller, Christine A.; Shaywitz, Adam J.; Gold, Jeffrey I..
J. inborn errors metab. screen
; 5: e170008, 2017. tab, graf
Artigo
em Inglês
|
LILACS-Express
| ID: biblio-1090939
Abstract Patients with mucopolysaccharidosis (MPS), and Morquio A syndrome (MPS IVA) in particular, often report substantial pain burden. MOR-008 was a randomized, double-blind, pilot study assessing the safety and efficacy, including impact on patient-reported pain, of 52 weeks of treatment with elosulfase alfa (at a dose of 2.0 or 4.0 mg/kg/week) in patients with Morquio A syndrome (?7 years old). Assessment of pain at baseline revealed that patients (N = 25) had a mean number of pain locations of 5.7, mean pain intensity score of 4.6 (indicative of medium pain), and a mean number of selected pain descriptors of 7.4 words. Treatment with elosulfase alfa improved subjective pain score (reduced to 3.2), pain locations (reduced by a mean of 1 location), and pain descriptor words (reduced to 4.9 words) over 1 year (52 weeks), suggesting that elosulfase alfa can reduce pain in some patients with Morquio A.
Biblioteca responsável:
BR1.1
Texto completo
Documentos relacionados